

# The Canadian Journal of Neurological Sciences

# Le Journal Canadien des Sciences Neurologiques



## SPECIAL FEATURES


<b>In Memoriam: Dr. André Barbeau (1931-1986)</b> .....	R.T. Ross	203
<b>CJNS Exchanges with Journals of Latin America, China and Eastern Europe</b> .....	Harvey B. Sarnat	205
<b>Traditional Chinese Herbs in Treatment of Neurological and Neurosurgical Disorders</b> .....	Yuji Ding and Xiaoxian He	210

## ORIGINAL ARTICLES

<b>Pharmacological Modification of Bradykinin Induced Breakdown of the Blood-brain Barrier</b> .....	Jennifer J. Raymond, David M. Robertson, and Henry B. Dinsdale	214
<b>Chiari Malformation in Adults: A Review of 40 Cases</b> ..	David D.R. Eisenstat, Mark Bernstein, J.F. Ross Fleming, R.G. Vanderlinden and Hart Schutz	221
<b>Seizures Associated with Spontaneous Subarachnoid Hemorrhage</b> .....	M.B.M. Sundaram and F. Chow	229
<b>The Posterior Cerebral Artery Syndrome</b> .....	C.M. Fisher	232
<b>Cerebral Evoked Potentials in Multiple Sclerosis</b> .....	Manouchehr Javidan, Donald R. McLean and Kenneth G. Warren	240
<b>The Treatment of the Restless Legs Syndrome with Clonazepam: A Prospective Controlled Study</b> .....	Dan Boghen, Lise Lamothe, Robert Elie, Roger Godbout and Jacques Montplaisir	245
<b>Parkinson's Disease: A Genetic Study</b> .....	Ma. Elisa Alonso, Enrique Otero, Rosalinda D'Regules and Hector Hugo Figueroa	248
<b>Free and Total Serum Valproate Concentrations: Their Relationship to Seizure Control, Liver Enzymes and Plasma Ammonia in Children</b> .....	Kevin Farrell, Frank S. Abbott, James M. Orr, Derek A. Applegarth, James E. Jan and Peter K. Wong	252
<b>Electroencephalograms of Children with Permanent Cortical Visual Impairment</b> .....	Robyn Robertson, James E. Jan and Peter K.H. Wong	256
<b>Cardiac Tachyarrhythmias in Hereditary Long QT Syndromes Presenting as a Seizure Disorder</b> .....	M.B.M. Sundaram, J.D. McMeekin and S. Gulamhusein	262
<b>Hereditary Motor Sensory Neuropathy Type 1 Presenting as Scapulothoracic Atrophy (Davidenkow Syndrome) Electrophysiological and Pathological Studies</b> .....	Gabriel M. Ronen, Noel Lowry, John H. Wedge, Harvey B. Sarnat and Alan Hill	264
<b>Swallow Syncope</b> .....	A. Guberman and J. Catching	267
<b>Multiple Sclerosis Presenting as Isolated Oculomotor Nerve Palsy</b> .....	Ryan J. Uitti and A.H. Rajput	270
<b>Book Reviews</b> .....		273
<b>Notes and Announcements</b> .....		277
<b>Calendar of Events</b> .....		278
<b>Erratum</b> .....		278
<b>Abstracts of the Canadian meeting of neuro-oncology/Réunion canadienne de neuro-oncologie</b> .....		279

## The Official Journal of

The Canadian Neurological Society  
The Canadian Neurosurgical Society  
The Canadian Society of Clinical Neurophysiologists  
The Canadian Association for Child Neurology



# FOR THE VASCULAR HEAD PAIN PUZZLE





**CAFERGOT<sup>®</sup>**  
To **ABORT** acute  
vascular headache

**SANDOMIGRAN<sup>®</sup> DS**  
PROPHYLAXIS for chronic  
recurring vascular headache

**SANDOZ<sup>®</sup>**



Complete headache therapy  
Sandoz Canada Inc., Dorval, Quebec H9R 4P5

Cafergot contains: ergotamine tartrate/caffeine © TM  
Sandomigran DS contains: pizotyline  
Full prescribing information available on request.    



**Editor/Rédacteur en chef** Robert G. Lee *Calgary*  
**Associate Editors/Rédacteurs associés** Harvey B. Sarnat *Calgary*  
**Founding Editor/Fondateur-rédacteur** Robert T. Ross *Winnipeg*  
**Book Review Editor/Rédacteur de critiques de livres** T. Peter Seland *Calgary*  
**Managing Editor/Adjoint administratif** Sally A. Gregg *Calgary*  
**News Editor/Rédacteur des Nouvelles** Thomas P. Morley *Toronto*

**Editorial Board/Conseil Scientifique**

Albert J. Aguayo <i>Montreal</i>	André Olivier <i>Montreal</i>
Henry J.M. Barnett <i>London</i>	Donald Paty <i>Vancouver</i>
Larry Becker <i>Toronto</i>	Sidney J. Peerless <i>London</i>
Paul Bédard <i>Quebec</i>	Terry Picton <i>Ottawa</i>
George Ebers <i>London</i>	Jean Reiher <i>Sherbrooke</i>
Guy Geoffroy <i>Montreal</i>	Leo P. Renaud <i>Montreal</i>
Yves Lamarre <i>Montreal</i>	Matthew W. Spence <i>Halifax</i>
William J. Logan <i>Toronto</i>	John Stewart <i>Montreal</i>
Morton Low <i>Vancouver</i>	Charles Tator <i>Toronto</i>
John Murphy <i>Toronto</i>	Simon Verret <i>Quebec</i>
Thomas J. Murray <i>Halifax</i>	Bryce Weir <i>Edmonton</i>

**Publications Committee/Comité de Rédaction**

John Wherrett <i>Toronto</i>	Warren Blume <i>London</i>
Terry Myles <i>Calgary</i>	John Tibbles <i>Halifax</i>

**The Official Journal of:/La Revue Officielle de:**

**The Canadian Neurological Society**

**La Société Canadienne de Neurologie**

President/Président — T. Peter Seland  
Secretary-Treasurer/ — William McCormick,  
Secrétaire-Trésorier Box 2148, Dickson Centre,  
Victoria General Hospital,  
Halifax, Nova Scotia  
B3H 2Y9

**The Canadian Society of Clinical Neurophysiologists**

**La Société Canadienne de Neurophysiologues Clinics**

President/Président — R. Gordon Blair  
Secretary-Treasurer/ — Werner J. Becker,  
Secrétaire-Trésorier 841 Centre Avenue East,  
Calgary, Alberta  
T2E 0A1

**The Canadian Neurosurgical Society**

**La Société Canadienne de Neurochirurgie**

President/Président — Francis E. LeBlanc  
Secretary-Treasurer/ — Alain Godon,  
Secrétaire-Trésorier 12361 Notre-Dame-des-Anges St.,  
Montreal, Quebec  
H4J 2C3

**The Canadian Association for Child Neurology**

**L'Association Canadienne de Neurologie Pédiatrique**

President/Président — Robert H.A. Haslam  
Secretary-Treasurer/ — Daniel Keene,  
Secrétaire-Trésorier Suite 208, 150 Montreal Road,  
Vanier, Ontario  
K1L 8H2

*The Canadian Journal of Neurological Sciences* is published quarterly by University of Calgary Press. The annual subscription rate is \$40.00 for Canada and the U.S.A. \$44.00 elsewhere. Interns, Residents Pre- and Post-Doctoral Students \$20.00 per annum. Single copies \$12.00 each. All communications and subscriptions should be sent to the Editor, Canadian Journal of Neurological Sciences, Room 1496, Faculty of Medicine, University of Calgary, 3330 Hospital Drive N.W., Calgary, Alberta, Canada T2N 4N1. Telephone: (403) 220-3062. COPYRIGHT © 1986 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Mailed under second class registration number 3307. Postage paid at Calgary, Alberta. This journal is indexed by *Index Medicus*, *Excerpta Medica* and *Current Contents — Clinical Practice and Life Sciences*.

*Le Journal Canadien des Sciences Neurologiques* est publié trimestriellement par les Presses de l'Université de Calgary. L'abonnement annuel est de \$40.00 pour le Canada et les Etats-Unis; \$44.00 ailleurs. Internes, résidents, fellows pré et post-doctoral: \$20.00 par an. Toutes les communications et les abonnements doivent être adressés à l'Editeur, Journal des Sciences Neurologiques, chambre 1496, Faculté de Médecine, Université de Calgary, 3330 Hospital Drive N.W., Calgary, Alberta, T2N 4N1. Téléphone (403) 220-3062. DROITS D'AUTEUR © 1986: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la permission préalable du Journal Canadien des Sciences Neurologiques. Posté sous permis de second classe no 3307. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *Index Medicus*, *Excerpta Medica* et *Current Contents — Clinical Practice et Life Sciences*.

**Advertising representative/Représentant de publicité** Keith Health Care Communications,  
4953 Dundas St. W., Toronto, Ontario, Canada M9A 1B6 — (416) 239-1233

**Printer/Imprimeur** McAra Printing Limited, 105, 2507 - 12th Street N.E., Calgary, Alberta T2E 7L5


ISSN 0317 - 1671

# CONFRONT THE REALITIES OF PARKINSON'S DISEASE

## Problems of long-term therapy with levodopa compounds

- Performance fluctuations
- End-of-dose deterioration
- Early morning stiffness
- On-off phenomenon

## During the course of a day<sup>(1)</sup>



Once a clear pattern is determined, two treatment approaches are possible:

- Add **PARLODEL** and/or
- More frequent, smaller doses of levodopa



Add **PARLODEL**<sup>®</sup>  
(bromocriptine mesylate)

For improved quality of life


A case of study: Wearing-off of levodopa



After an average of seven years of therapy with levodopa compounds, adding Parlodel resulted in...<sup>(2)</sup>

A reduced severity of levodopa complications


% patients improved



Adapted from the Hoehn Study<sup>(2)</sup>.  
Parlodel dose range: 12.4-20 mg/day

An improvement in mean neurological scores

% improvement



Adapted from the Hoehn Study<sup>(2)</sup>.  
Maximum Parlodel dosage: 20 mg/day

**PARLODEL**<sup>®</sup>  
(bromocriptine mesylate)

An effective alternative to increased levodopa

**SANDOZ**<sup>®</sup>

PAAB  
CCPP

LISTED ON ALL  
PROVINCIAL  
FORMULARIES

# ADD<sup>®</sup> PARLODEL<sup>®</sup>

(bromocriptine mesylate)

## For added control

**ACTIONS** Parlodel (bromocriptine mesylate) is a dopaminomimetic ergot derivative with D<sub>2</sub> type dopamine receptor agonist activity, and has also D<sub>1</sub> dopamine receptor antagonist properties. The dopaminomimetic activity of bromocriptine in the striatum is considered responsible for the clinical benefits seen in selected patients with Parkinson's Disease, when low doses of the drug are gradually added to levodopa therapy in patients on long-term treatment who develop late side effects of levodopa or no longer respond to the medication. Excessive dopaminomimetic drive may, however, provoke psychotic and other adverse reactions.

The extreme variability in G.I. tract absorption, and the extensive and individually variable first-pass metabolism is responsible for the broad variability in plasma concentrations of bromocriptine and, in part, for the variability in dose response.

**INDICATIONS\*** **Parkinson's Disease:** Parlodel (bromocriptine mesylate) has been found to be clinically useful as an adjunct to levodopa (usually with a decarboxylase inhibitor), in the symptomatic management of selected patients with Parkinson's Disease who experience prominent dyskinesia or wearing off reactions on long-term levodopa therapy.

Patients on long-term treatment who are beginning to deteriorate on levodopa therapy may be controlled by reducing the dose of levodopa and adjusting the frequency and schedule of drug administration. Patients maintained on optimal dosages of levodopa who still experience prominent dyskinesia and/or end-of-dose failure, may benefit from the concomitant use of Parlodel, by decreasing the occurrence and/or severity of these manifestations. Since rapid escalation of bromocriptine doses causes severe adverse reactions, it is recommended to combine a slow increase of Parlodel, usually with a concomitant, gradual and limited reduction of levodopa dosage. Continued efficacy of bromocriptine for more than two years has not been established and there is some evidence that its efficacy tends to wane. Evidence available indicates that there is no consistent benefit from bromocriptine in patients who have not responded previously to levodopa, and studies have shown significantly more adverse reactions in bromocriptine treated patients than in patients treated with levodopa. Parlodel is not recommended in the treatment of newly diagnosed patients or as the sole medication in Parkinson's Disease.

**CONTRAINDICATIONS** Other than sensitivity to ergot alkaloids, no absolute contraindications to treatment with Parlodel (bromocriptine mesylate) are known. For procedure during pregnancy see "Use in Pregnancy" under Precautions.

**WARNINGS** Long-term treatment (6-36 months) with Parlodel in doses of 20 to 100 mg/day has been associated with pulmonary infiltrates, pleural effusion and thickening of the pleura in a few patients. Where Parlodel was discontinued, these changes slowly reverted to normal.

**PRECAUTIONS** Parlodel (bromocriptine mesylate) may cause hypotension, primarily postural; periodic monitoring of the blood pressure, particularly during the first days of therapy, is advisable. In some patients dizziness (vertigo) may occur with Parlodel; patients should therefore be cautioned against activities requiring rapid and precise responses such as driving an automobile or operating dangerous machinery until their response has been determined.

Care should be exercised when administering Parlodel concomitantly with phenothiazines or antihypertensive agents. Due to drug interaction at the receptor site, dosage should be adjusted accordingly.

Alcohol should be avoided during treatment with Parlodel. In some patients, the concomitant use of Parlodel and alcohol has given rise to alcohol intolerance and an increase in the severity and incidence of Parlodel's possible adverse reactions.

Parlodel should always be taken with food. In cases where severe adverse effects, such as nausea, vomiting, vertigo or headaches are severe or persisting, the therapeutic dosage of Parlodel should be reduced to one-half tablet daily (1.25 mg) and increased gradually to that recommended.

As with all medication, Parlodel should be kept safely out of the reach of children.

**Use in Pregnancy** If the patient wishes to become pregnant, Parlodel (bromocriptine mesylate) should be stopped as soon as possible after conception is suspected. In this event immunological confirmation should be done immediately. When pregnancy is confirmed, Parlodel, like all other drugs, should be discontinued unless, in the opinion of the treating physician, the possible benefit to the patient outweighs the potential risk to the fetus.

In human studies with Parlodel (reviewed by Turkali, I.), there were 1410 reported pregnancies, which yielded 1236 live and 5 stillborn infants from women who took Parlodel (bromocriptine mesylate) during early pregnancy. Among the 1241 infants, 43 cases (31 minor and 12 major) of congenital anomalies were reported. The incidence (3.46%) and type of congenital malformations and the incidence of spontaneous abortions (11.13%) in this group of pregnancies does not exceed that generally reported for such occurrences in the population at large.

**Gynecological Supervision** All women patients receiving Parlodel continuously for six months or more should have a gynecological examination before therapy, yearly if still menstruating, and six-monthly if menopausal. The examination should include cervical and, if possible, endometrial cytology. Post-menopausal women on estrogen therapy should be excluded from Parlodel therapy at the discretion of the physician because estrogen induced uterine bleeding may mask the presence of pathological lesions.

A lifetime rat study revealed that some animals developed uterine tumors and endometrial carcinoma thought to be due to a state of induced estrogen dominance. However, clinical experience in women with a variety of hyperprolactinemic and other conditions, treated with Parlodel for months or years, failed to demonstrate abnormal trends in hormonal levels or in endometrial cytology.

Normoprolactinemic women treated with Parlodel should be given the lowest effective dose necessary to relieve their symptoms, in order to avoid the possibility of suppression of prolactin below normal levels, with a consequent impairment of luteal function.

**Use in Parkinson's Disease:** Use of Parlodel (bromocriptine mesylate), particularly in high doses, may be associated with mental confusion and mental disturbances. Since patients with Parkinson's Disease may manifest varying degrees of dementia, caution should be exercised when treating such patients with Parlodel.

Parlodel administered alone or concomitantly with levodopa may cause visual or auditory hallucinations. These usually resolve with dosage reduction, but discontinuation of Parlodel may be required in some cases. Rarely, after high doses, have hallucinations persisted for several weeks following discontinuation of Parlodel. Caution should be exercised when administering Parlodel to patients with a history of myocardial infarction, particularly if they have a residual atrial, nodal or ventricular arrhythmia.

Symptomatic hypotension can occur and, therefore, caution should be exercised when administering Parlodel, particularly in patients receiving antihypertensive medication. Periodic evaluation of hepatic, hematopoietic, cardiovascular and renal function is recommended.

**Drug Interactions:** The concomitant use of erythromycin may increase bromocriptine plasma levels.

**ADVERSE REACTIONS** The most frequently observed adverse reactions are nausea, vomiting, headache and gastrointestinal side effects such as abdominal pain, diarrhea and constipation. All these effects may be minimized or even prevented by giving small initial doses of bromocriptine and by taking it with food.

Postural hypotension which can, on rare occasions, lead to fainting and "shock-like" syndromes have been reported in sensitive patients. This is most likely to occur during the first few days of Parlodel treatment.

When bromocriptine is added to levodopa therapy, the incidence of adverse reactions may increase. The most common newly appearing adverse reactions in combination therapy were: nausea, abnormal involuntary movements, hallucinations, confusion, "on-off" phenomenon, dizziness, drowsiness, faintness, vomiting, asthenia, abdominal discomfort, visual disturbance, ataxia, insomnia, depression, hypotension, shortness of breath, constipation and vertigo.

Less common adverse reactions include, anorexia, anxiety, blepharospasm, dry mouth, dysphagia, edema of the feet and ankles, erythromelalgia, epileptiform seizures, fatigue, headache, lethargia, mottling of skin, nasal stuffiness, nervousness, nightmares, paresthesia, skin rash, urinary frequency, urinary incontinence, urinary retention and rarely signs of symptoms of ergotism such as tingling of fingers, cold feet, numbness, muscle cramps of feet and legs or exacerbation of Raynaud's syndrome.

Abnormalities in laboratory tests may include elevation of blood urea nitrogen, SGOT, SGPT, GGPT, CPK, alkaline phosphatase and uric acid, which are usually transient and not of clinical significance.

The occurrence of adverse reactions may be lessened by temporarily reducing dosage to one-half tablet two or three times daily.

### **SYMPTOMS AND TREATMENT OF OVERDOSE**

There have been several reports of acute overdose with Parlodel (bromocriptine mesylate) in children and adults. No life threatening reactions have occurred. Symptoms reported included nausea, vomiting, dizziness, drowsiness, hypotension, sweating and hallucinations. Management is largely symptomatic; the cardiovascular system should be monitored. Metoclopramide can be used to antagonize the emesis and hallucinations in patients who have taken high doses.

**DOSEAGE AND ADMINISTRATION** Parlodel (bromocriptine mesylate) should always be taken with food.

Although Parlodel (bromocriptine mesylate) has been found clinically useful in decreasing the severity and frequency of "on-off" fluctuations of late levodopa therapy, the decision to use bromocriptine as adjunctive treatment and the selection of dosage must be individualized in each case. A low dose is recommended. The initial dose of Parlodel is one half of a 2.5 mg tablet (1.25 mg) at bedtime with food to establish initial tolerance. Thereafter, the recommended dosage is 2.5 mg daily in two divided doses, with meals, (half a 2.5 mg tablet twice daily). The dosage may be increased very gradually, if necessary, by adding an additional 2.5 mg per day, once every 2 to 4 weeks, to be taken always in divided doses with meals. Increments should usually never exceed 2.5 mg. Clinical assessments are recommended at two week intervals or less during dosage titration, to ensure that the lowest effective dosage is not exceeded. The usual dosage range is from a few milligrams to 40 mg daily in two or three divided doses with meals. The median dose varies with the experience of individual investigators, but can be around 10 mg daily or higher. During initial titration it is recommended that the dosage of levodopa should be maintained, if possible. Subsequently, it might be desirable to combine a slow increase of bromocriptine with a concomitant, limited and gradual reduction of levodopa.

### **AVAILABILITY**

1. TABLETS each containing 2.5 mg bromocriptine, as mesylate, available in bottles of 100.  
Scored 7 mm, round compressed white tablets with "XC" on one side and "PARLODEL" on the reverse.
2. CAPSULES each containing 5 mg bromocriptine, as mesylate, available in bottles of 100. Caramel and white size 3 hard shell capsules with "PARLODEL" on one side and "5 mg" on the other.

### **REFERENCES:**

1. Grimes J.D. Medical Review Series (Handbook No. 4) 1984;14
2. Hoehn M, Elton RL. Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985;35:199-206



2.5 mg  
scored tablet



5 mg  
capsule

PAAB  
CCPP

\* For information on other approved indications, please consult the Parlodel product monograph, available to physicians and pharmacists on request.

SANDOZ  
Sandoz Canada Inc.  
Dorval, Quebec  
H9R 4P5



DANTEC

DANTEC Electromedical & Scientific Equipment Ltd.  
140 Shorting Road, Scarborough, Ontario, M1S 3S6, Canada  
Phone: (416) 298-2091 – Telex: 065-25137

# Evomatic® 4000/8000

– for evoked potentials in:

### Neurophysiology

Evaluation of Tumors, Traumas, Degenerative and Vascular diseases.

### Psychology & Psychiatry

The study of Language, Performance, Senile Dementia and Psychosis.

### Otolaryngology

Early detection of Tumors, Lesions of the Cochlear Organ and the Brain Stem.

### Ophthalmology

Separating Retinal Lesions from Opacities in the Refractory Media.

### Surgery




Intraoperative monitoring during surgery of Spine, Heart, Eye and Posterior Fossa.

### Pediatrics

Assessment of Hearing and Visual Acuity.

### Research

In Neurophysiology, Drug Industry, Psychology, Space Science, etc.



**Auditory**  
Objective Hearing Level 50 dB

# SERC®

(betahistine hydrochloride tablets)

## For the management of Vertigo

### ■ Proven efficacy

"(Serc) is now a proven, useful therapeutic agent in the treatment of Ménière's disease, especially in the control of vertigo."<sup>1</sup>

### ■ Restores vestibular responses

"In a preliminary trial (Wilmot 1971) using objective testing of both auditory and vestibular function,...the results showed statistical significance in favour of Serc."<sup>2</sup>

### ■ Reduced severity of episodic vertigo

"...a significant improvement in favour of the drug (Serc) with regard to vertigo, tinnitus and deafness. Vertigo was the most responsive symptom."<sup>1</sup>

### ■ Well tolerated

"No adverse reactions were observed."<sup>1</sup>

#### REFERENCES:

<sup>1</sup>Frew, I.J.C. et al: Postgrad. Med. J.: 52:501-503, 1976.

<sup>2</sup>Wilmot, T.J. et al: J. Laryng. Otol: 9:833-840, 1976.

#### PRESCRIBING INFORMATION

**INDICATIONS:** SERC may be of value in reducing the episodes of vertigo in Ménière's disease. No claim is made for the effectiveness of SERC in the symptomatic treatment of any form of vertigo other than that associated with Ménière's disease.

**DOSAGE AND ADMINISTRATION:** The usual adult dosage has been one to two tablets (4 mg. each) administered orally three times a day.

Recommended starting dose is two tablets three times daily. Therapy is then adjusted as needed to maintain patient response. The dosage has ranged from two tablets per day to eight tablets per day. No more than eight tablets are recommended to be taken in any one day.

SERC (betahistine hydrochloride) is not recommended for use in children. As with all drugs, SERC should be kept out of reach of children.

**CONTRAINDICATIONS:** Several patients with a history of peptic ulcer have experienced an exacerbation of symptoms while using SERC. Although no causal relation has been established SERC is contraindicated in the presence of peptic ulcer and in patients with a history of this condition. SERC is also contraindicated in patients with pheochromocytoma.

**PRECAUTIONS:** Although clinical intolerance to SERC by patients with bronchial asthma has not been demonstrated, caution should be exercised if the drug is used in these patients.

**USE IN PREGNANCY:** The safety of SERC in pregnancy has not been established. Therefore, its use in pregnancy or lactation, or in women of childbearing age requires that its potential benefits be weighed against the possible risks.

**ADVERSE REACTIONS:** Occasional patients have experienced gastric upset, nausea and headache.

**HOW SUPPLIED:** Scored tablets of 4 mg each in bottles of 100 tablets.

Full prescribing information available on request.



**UNIMED** Canada Inc.

PAAB  
CCPP



# Something to live for



**P**arkinson's syndrome is an insidious assault on the lifestyles of more than 58,000 Canadians.

**F**or these individuals, daily, routine habits like knotting a tie, or pinning the hair, are often impossible tasks.

**S**ymmetrel® can help many of these patients gain a better hold on their daily lives, and helps you to control the syndrome.

**A**s initial, or adjunctive therapy, Symmetrel® for Parkinson's syndrome offers:

- few significant side effects, even after long-term use.<sup>1</sup>
- noticeable benefits within 24 hours of start-up dose.<sup>1</sup>
- easy usage with levodopa and anticholinergics.<sup>1</sup>
- simple dosage regimen; simple titration.

**SYMMETREL**<sup>®</sup>  
(amantadine HCl)

can help in Parkinson's Disease

For brief prescribing information see page xv

**Du Pont Pharmaceuticals**  
Mississauga, Ontario  
LSM 2J4



® TM

PAAB  
CCPP

# ANOTHER UNEVENTFUL DAY.

## DILANTIN

Extended Phenytoin Sodium Capsules, U.S.P.  
100 mg  
ANTICONSULSANT

### INDICATIONS

Dilantin is indicated for the control of generalized tonic-clonic (grand mal) seizures and complex partial (psychomotor) seizures.

### CONTRAINDICATIONS

Dilantin is contraindicated in those patients with a history of hypersensitivity to hydantoin products.

### WARNINGS

Abrupt withdrawal of phenytoin in epileptic patients may precipitate status epilepticus.

Phenytoin is not indicated in seizures due to hypoglycemia or other causes which may be immediately identified and corrected.

Phenytoin metabolism may be significantly altered by the concomitant use of other drugs such as:

**A.** Barbiturates may enhance the rate of metabolism of phenytoin. This effect, however, is variable and unpredictable. It has been reported that in some patients the concomitant administration of carbamazepine resulted in an increased rate of phenytoin metabolism.

**B.** Coumarin anticoagulants, disulfiram, phenylbutazone, and sulfaphenazole may inhibit the metabolism of phenytoin, resulting in increased serum levels of the drug. This may lead to an increased incidence of nystagmus, ataxia, or other toxic signs.

**C.** Isoniazid inhibits the metabolism of phenytoin so that with combined therapy, patients who are slow acetylators may suffer from phenytoin intoxication.

**D.** Tricyclic antidepressants in high doses may precipitate seizures, and the dosage of phenytoin may have to be adjusted accordingly.


**Usage in Pregnancy:** The effects of Dilantin in human pregnancy and nursing infants are unknown.

The prescribing physician will have to determine the risk/benefit in treating or counselling epileptic women of childbearing potential.

### PRECAUTIONS

The liver is the chief site of biotransformation of phenytoin, patients with impaired liver function may show early signs of toxicity. Elderly patients or those who are gravely ill may show early signs of toxicity.

A small percentage of individuals who have



See Alternative Dose

been treated with phenytoin have been shown to metabolize the drug slowly. Slow metabolism may be due to limited enzyme availability and lack of induction; it appears to be genetically determined.

Phenytoin has been associated with reversible lymph node hyperplasia. If lymph node enlargement occurs in patients on phenytoin, every effort should be made to substitute another anticonvulsant drug or drug combination.

Drugs that control generalized tonic-clonic (grand mal) seizures are not effective for absence (petit mal) seizures. Therefore, if both conditions are present, combined drug therapy is needed.

Hyperglycemia, resulting from the drug's inhibitory effect on insulin release, has been reported. Phenytoin may also raise the blood sugar level in persons already suffering from hyperglycemia.

### ADVERSE REACTIONS

**Central Nervous System:** The most common manifestations encountered with phenytoin therapy include nystagmus, ataxia, slurred speech, and mental confusion. Dizziness, insomnia, transient nervousness, motor twitchings, and headache have also been observed. These side effects may disappear with continuing therapy at a reduced dosage level.

**Gastrointestinal System:** Phenytoin may cause nausea, vomiting, and constipation. Administration of the drug with or immediately after meals may help prevent gastrointestinal discomfort.

**Integumentary System:** Dermatological manifestations sometimes accompanied by fever have included scarlatiniform or morbiliform rashes.

**Hemopoietic System:** Hemopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia.

**Other:** Gingival hyperplasia occurs frequently; this incidence may be reduced by good oral hygiene including gum massage, frequent brushing and appropriate dental care. Polyarthropathy and hirsutism occur occasionally. Hyperglycemia has been reported. Toxic hepatitis, liver damage, and periarteritis nodosa may occur and can be fatal.

### MANAGEMENT OF OVERDOSE

The mean lethal dose in adults is estimated to be 2 to 5 grams. The cardinal initial symptoms are nystagmus, ataxia and dysarthria. The patient then becomes comatose, the pupils are unresponsive and hypotension occurs. Death is due to respiratory depression and apnea. Treatment is nonspecific since there is no known antidote. First, the stomach should be emptied. If the gag reflex is absent, the airway should be supported. Oxygen, vasopressors and assisted ventilation may be necessary for central nervous system, respiratory and cardiovascular depression. Finally, hemodialysis can be considered since phenytoin is not completely bound to plasma proteins.

### DOSAGE AND ADMINISTRATION

Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations may be necessary for optimal dosage adjustments — the clinically effective serum level is usually 10-20 mcg/mL.

**Adult Dose:** Patients who have received no previous treatment may be started on one 100 mg Dilantin Capsule three times daily and the dose then adjusted to suit individual requirements.

**Pediatric Dose:** Initially, 5 mg/kg/day in two or three equally divided doses, with subsequent dosage individualized to a maximum of 300 mg daily. A recommended daily maintenance dosage is usually 4 to 8 mg/kg. Children over 6 years old may require the minimum adult dose (300 mg/day). Pediatric dosage forms available include a 30 mg Capsule, a 50 mg palatably flavoured Infatab, or an oral suspension form containing 30 or 125 mg of Dilantin in each 5 mL.

**Alternative Dose:** Once-a-day dosage for adults with 300 mg of Dilantin may be considered if seizure control is established with divided doses of three 100 mg Capsules daily.

### HOW SUPPLIED

Dilantin 100 mg Capsules; in bottles of 100 & 1000.

Complete prescribing information available upon request.

*Dilantin. Start with it. Stay with it.*

**PARKE-DAVIS**

Parke-Davis Canada Inc., Scarborough, Ontario



\*Reg. T.M. Parke, Davis & Company, Parke-Davis Canada Inc., auth. user



See IBC

# HOLD IT!



For the treatment of Parkinson Syndrome –  
“levodopa, combined with a decarboxylase  
inhibitor, remains the best treatment for  
most patients.”<sup>1</sup>

In most Parkinsonian patients ‘Prolopa’:

- improves motor movement rapidly<sup>2</sup>
- achieves high serum levels quickly<sup>2</sup>
- minimizes common side effects like nausea  
and vomiting
- all three ‘Prolopa’ dose forms contain  
the established 4:1 ratio

The use of the 4:1 levodopa/decarboxylase  
inhibitor combination has been shown to  
reduce significantly the incidence of side  
effects attributed to the 10:1 ratio<sup>3,4,5</sup>


**Prolopa**<sup>®</sup>  
(levodopa/benserazide) 4:1

Helps return the simple pleasures of living.



For brief prescribing information see page XIX

# Productive Antispastic



Without Therapy.



With Oversedation.

## Information for Authors

The Canadian Journal of Neurological Sciences publishes original articles in the clinical and basic neurosciences. Manuscripts are considered for publication with the understanding that, except for identified review articles, they have not been published elsewhere except in abstract form and are not under simultaneous consideration by another publication. Manuscripts should be submitted to:

The Editor  
Canadian Journal of Neurological Sciences  
Faculty of Medicine,  
University of Calgary  
3330 Hospital Drive N.W.  
Calgary, Alberta T2N 4N1

Manuscripts and all illustrations should be submitted in triplicate. Papers will be accepted in English or French. All papers should be accompanied by an abstract or a résumé of approximately 150 words on a separate page, preferably in both languages, although the Journal will provide the translation if requested. All manuscripts should be double spaced throughout, including references and legends for illustrations. Margins of at least 25 mm should be left on all sides.

For detailed instructions regarding style and layout, authors should refer to "Uniform requirements for manuscripts submitted to biomedical journals". Copies of this document may be obtained by writing to the Journal office, but the main points will be summarized here. Articles should be subdivided under conventional headings of "introduction", "methods and materials", "results" and "discussion" but other headings and subheadings will be considered if more suitable for a particular manuscript. A title page should identify the title of the article, authors, name of institution(s) from which the work originated, and the address and telephone number of the author to whom communications should be addressed. Pages of text should be numbered consecutively. Acknowledgements, including recognition of financial support, should be typed on a separate page at the end of the text.

**References** are to be numbered in the order of citation in the text. Those cited only in tables or in legends for illustrations are numbered in accordance with a sequence established by the first identification in the text of a particular table or illustration. Titles of journals should be abbreviated according to the style used in *Index Medicus*. References should be complete including the names of the first three authors followed by "et al"

if there are more than three authors, full title, year of publication, volume number, and inclusive pagination for journal articles. Book or chapter references should also include the place of publication and name of the publisher. Examples of correct forms of references follow:

### Journals

Poirier LJ, Filion M, Larochelle L, et al. Physiopathology of experimental parkinsonism in the monkey. *Can J Neurol Sci* 1975; 2: 255-263

### Chapter in a book

McGeer PL, McGeer EG. Amino acid neurotransmitters. In: Siegel GJ, Albers RW, Agranoff BW, Katzman R, eds. *Basic Neurochemistry*. Boston: Little, Brown & Co, 1981: 233-254

**Illustrations** should be high quality glossy black-and-white photographic prints, preferably 127 x 173 mm (5 x 7"). Original artwork and radiographs should not be submitted. The additional cost of colour illustration must be borne by the author; quotations are available upon request from the Journal office. All figures should be identified on the back with the author's name and figure number. Letters and arrows applied to the figures to identify particular findings should be professional appliques suitable for publication. Photomicrographs should include a calibration bar with the scale indicated on the figure or in the legend. Legends for illustrations should be typed on a separate page from the illustrations themselves.

**Tables** should each be on a separate page and be identified with the title or heading. Particular care should be taken in the preparation of tables to ensure that the data are presented in the most clear and precise format. Each column should have a short or abbreviated heading. Place explanatory matter in footnotes, not in the heading. Do not submit tables as photographs.

The SI system (système international d'unités) should be used in reporting all laboratory data, even if originally reported in another system. Temperatures are reported in degrees Celsius. Other measurements should be reported in the metric system. English language text may use either British or American spelling, but should be consistent throughout.

**Review articles** on selected topics also are published by the Journal. These are usually invited, but unsolicited reviews will be considered. It is suggested that authors intending to submit reviews contact the Editor in advance.

**Letters to the Editor** are welcome. These should be limited to two double-spaced pages and may include one illustration and a maximum of four references.

# Therapy Is a Fine Art.



With Lioresal.

Successful rehabilitation requires both spinal spasticity control and alertness. And that's why Lioresal® stands out.

Lioresal can control painful flexor spasms, but unlike diazepam, oversedation is rarely a problem<sup>(1,2,3)</sup>.

And it effectively stops most flexor spasms overnight, so patients can sleep naturally.

Now there's two strengths:

Lioresal 10mg to initiate therapy and Lioresal D.S. 20mg for maintenance.

Considering that Lioresal has an excellent long-term safety profile, it may be your most effective choice for long-term control of spinal spasticity.

(baclofen)  
**Lioresal**

Lioresal 10mg (initiation therapy)

Lioresal D.S. 20mg (maintenance therapy)

**Geigy**

Mississauga, Ontario  
LSN 2W5

PAAB  
CCPP  
G-9139

For brief prescribing information see page xvi

## Information aux Auteurs

Le Journal Canadien des Sciences Neurologiques publie des articles originaux dans les sciences neurologiques, cliniques et fondamentales. Les manuscrits ne sont considérés pour publication qu'à la condition expresse, à l'exception des articles de revue clairement identifiés comme tel, qu'ils n'aient pas été publiés ailleurs, sauf sous forme de résumé et qu'ils ne soient pas sous considération simultanée par un autre journal. Les manuscrits doivent être soumis à:

L'Editeur  
Journal Canadien des Sciences Neurologiques,  
Faculté de Médecine,  
Université de Calgary,  
3330 Hospital Drive, N.W.,  
Calgary, Alberta T2N 4N1

Les manuscrits et toutes les illustrations doivent être soumis en triplicata. Les articles seront acceptés en français ou en anglais. Tous les articles doivent être accompagnés d'un résumé d'environ 150 mots, sur page séparée, préférablement dans les deux langues, quoique le Journal puisse fournir cette traduction sur requête. Les manuscrits doivent être dactylographiés complètement à double interligne y compris les références et les légendes pour illustrations. Des marges d'au moins 25 mm doivent être laissées de tous les côtés.

Pour les conseils plus détaillés sur le style et la présentation du texte, les auteurs doivent se référer au texte intitulé "Règlements uniformes pour les manuscrits soumis aux journaux biomédicaux". On peut obtenir une copie de ce document en écrivant au bureau du Journal, mais en voici les principaux points: Les articles doivent être présentés selon le plan habituel: "Introduction", "Matériel et méthodes", "Résultats" et "Discussion", mais il est possible d'employer d'autres titres ou sous-titres si nécessaire pour un manuscrit en particulier. Sur une page titre séparée on doit identifier le titre de l'article, les auteurs, les institutions d'où origine le travail, ainsi que l'adresse et le numéro de téléphone de l'auteur à qui devront être adressées les communications. Les remerciements, incluant ceux pour l'appui financier, doivent être dactylographiés sur page séparée à la fin du texte. Les références doivent être numérotées dans l'ordre où elles sont citées dans le texte. Celles qui sont citées seulement dans les tableaux ou légendes d'illustrations sont numérotées selon la séquence établie par la première identification dans le texte de ces tableaux ou illustrations particulières. Les titres des Journaux doivent être abrégés selon le style utilisé dans Index Medicus. Les références doivent être complètes, incluant le nom des trois premiers auteurs suivis de "et al", s'il y a plus de trois auteurs, le titre complet, l'année de publication, le

numéro du volume et les premières et dernières pages de l'article. Les références aux livres et chapitres de livres doivent aussi inclure le lieu de la publication et le nom de la maison d'édition. Les exemples corrects suivants peuvent être utilisés:

### Journaux

Poirier LJ, Filion M, Larochelle L, et al. Physiopathology of experimental parkinsonism in the monkey. *Can J Neurol Sci* 1975; 2: 255-263

### Chapitre de livre

McGeer PL, McGeer EG, Amino acid neurotransmitters. In: Siegel GJ, Albers RW, Agranoff BW, Katzman R, eds. *Basic Neurochemistry*. Boston: Little, Brown & Co, 1981: 233-254

Les **illustrations** doivent être sur papier brillant de haute qualité et imprimés en blanc et noir, préférablement 127 x 173 mm (5 x 7"). Les illustrations et photographies originales ne doivent pas être soumises. Le coût supplémentaire des illustrations en couleur revient entièrement à l'auteur; les coûts détaillés peuvent être obtenus directement au bureau du Journal. Il faut identifier toutes illustrations en inscrivant au dos le nom de l'auteur et le numéro. Toutes lettres ou flèches appliquées aux illustrations pour identifier un aspect particulier doivent être de qualité professionnelle. Les photomicrographies doivent inclure une barre de calibration dont l'échelle est mentionnée dans la légende. Les légendes des illustrations doivent être dactylographiées sur une page séparée de celles-ci.

Les **tableaux** doivent être sur des pages séparées et être identifiés avec titre. On doit prendre un soin particulier dans la préparation de ces tableaux afin d'assurer que les données soient présentées avec le format le plus clair et le plus précis possible. Chaque colonne doit avoir un court titre. Les explications doivent être placées en dessous du tableau et non en sous-titre. Un tableau ne doit pas être soumis sous forme de photographie.


On doit employer le système international d'unités (SI) pour toutes données de laboratoire, même si celles-ci sont originellement présentées dans un autre système. Les températures doivent être citées en degrés Celcius. Les autres données doivent utiliser le système métrique. Les textes en anglais peuvent utiliser l'orthographe anglais ou américain, mais cet usage doit être constant.

Le Journal publie également des **articles de revue** sur des sujets sélectionnés. Ces articles sont généralement sur invitation, mais, à l'occasion, une revue non sollicitée peut être acceptée. Il serait préférable que les auteurs ayant l'intention de soumettre une telle revue contactent d'abord l'Editeur.

Nous accueillons les **lettres à l'Editeur**. Celles-ci doivent se limiter à deux pages, double interligne et peuvent contenir une seule illustration et ne citer qu'un maximum de quatre références.

Introducing  
the Nicolet CA2000

# Comprehensive Electrodiagnostics In the Nicolet Tradition of Quality



## Comprehensive Testing Capabilities

- Auditory Evoked Potential Testing: ABR, ECoG, MLR, 40 Hz, LLR, P300
- Visual Evoked Potential Testing: VEP, ERG, EOG
- Somatosensory Evoked Potential Testing: SEP, Dermatomes
- Facial Nerve Testing and Monitoring
- Electromyographic Testing: Needle EMG, NCV, F-Wave, H-Reflex, Repetitive Stimulation
- Electronystagmographic Testing
- Intraoperative Monitoring

## Our Commitment to Quality

In addition to providing you with a variety of hardware and software features, all of our electrodiagnostic systems are backed by:

- A full one-year warranty
- Comprehensive customer training
- Experienced full-time applications staff
- Our national/international service network
- Factory-trained service personnel
- Thorough, easy-to-read documentation
- Nicolet's 18 years of experience in the biomedical field

## Additional Information

To learn more about the Nicolet CA2000 or to schedule a demonstration, call 1-416-625-8302  
Nicolet Instrument Canada Inc.  
1-1200 Aerowood Drive,  
Mississauga, Ontario  
L4W 2S7

**Nicolet**  
Electrophysiology  
*Yesterday, Today, Tomorrow*

**American Epilepsy Society — American Electroencephalographic Society  
Joint Fortieth Anniversary Meeting  
November 15-22, 1986 — Seattle, Washington**

**DIDACTIC COURSES & WORKSHOPS**

November 15	Course: State of the Science in EEG, Evoked Potentials and Clinical Neurophysiology
November 16	Course: EEG as Related to Epilepsy; Pathophysiology of Epilepsy
November 17	Course: Clinical Pharmacology of Antiepileptic Drugs
	Investigators' Workshops: Debates on Controversial Issues
	Kindling, Experimental Models, Ictal-like Events in the Slice, Seizure Networks
	Evening: Surgery for Childhood Epilepsy, Topographic Mapping, Welcoming Reception

**SCIENTIFIC PROGRAM**

November 18	American EEG Society Presidential Address; Herbert H. Jasper Award Symposium I: Basic Mechanisms of Antiepileptic Drug Action; Poster & Platform Presentations Dinner Workshops: The Approach to EEG-Clinical Problems in Childhood; The EEG in Pre-Senile Dementias, Senility and Senescence; Motor Evoked Potentials; Computers and Data Bases
November 19	American Epilepsy Society Lennox Award and Lecture, Lennox Fellow and AES Award Symposium II: Sleep and Seizure Disorders; Poster & Platform Presentations Evening: Special Interest Groups
November 20	Symposium III & IV: Newer Applications of Evoked Potentials; Surgery of the Corpus Callosum Poster & Platform Presentations Evening: 40th Anniversary Reception and Banquet

**OTHER**

November 21	Merritt-Putnam Symposium: Pediatric Neurology, co-sponsored by Columbia University, AES and EFA
November 22	AES Symposium: Epilepsy and Behavior

**CONTACT:** American Epilepsy Society, 179 Allyn Street OR American EEG Society, 2579 Melinda Drive NE  
Suite 304, Hartford, CT 06103 (203-246-6566) Atlanta, GA 30345 (404-320-1746)

**ACCREDITATION:** This meeting is designed to provide an update for the academic neuroscientist and neurologist, practicing neurologist, neurosurgeon, internist and pediatrician. Both societies are accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. This CME activity is designated as meeting the criteria for up to 35 hours in Category I of the Physician's Recognition Award of the AMA.

**HANS BERGER POSTDOCTORAL  
FELLOWSHIP  
OF THE  
AMERICAN EEG SOCIETY**

The American EEG Society is pleased to announce a new postdoctoral fellowship award: the Hans Berger Research Fellowship. The one year fellowship award of \$25,000 is intended to provide an additional postdoctoral fellowship year for an M.D. who has completed his specialty training and is currently a Clinical Neurophysiology post-doctoral fellow in North America, but who requires an additional year to complete a clinical or basic research project. Deadline for receipt of fellowship applications is February 1, 1987, for an award beginning July 1, 1987. The recipient of the fellowship award will be announced during the month of March. Further information can be obtained from Fay S. Tyner, Executive Director, American EEG Society, 2579 Melinda Drive, N.E., Atlanta, GA 30345. (supported in part by matching funds contributed by Nihon-Kohden, Oxford Medilog, Neuro-Science and Raven Press).

**WILLIAM G. LENNOX  
POSTDOCTORAL  
FELLOWSHIP IN EPILEPSY  
OF THE  
AMERICAN EPILEPSY SOCIETY**

A one year William G. Lennox Postdoctoral Fellowship will be awarded in 1987 to a selected applicant with interests in epilepsy research. The Fellowship provides a stipend of \$25,000 and support to attend the yearly meeting following completion of the Fellowship. The Lennox Fellow is expected to present the results of his/her work at that time.

Candidates must have completed their doctoral training (Ph.D., M.D., or equivalent degree) by the time the Fellowship would begin. To apply, submit a Curriculum Vitae, a list of publications, and a letter from the sponsor (additional letters of reference are optional). Also, the proposed research should be described (which may relate to any aspect of epilepsy), including goals, scientific background, methods, significance, and research facilities available to support the project. This description should not exceed five pages. There is no formal application form.

Deadline for receipt of materials is **February 1, 1987**, for the Fellowship beginning July-September, 1987. Send materials (six copies) to: American Epilepsy Society, 179 Allyn Street, Suite 304, Hartford, CT 06103.

**FOR  
THE  
HEAD  
PAIN  
PUZZLE...**

**FIORINAL<sup>®</sup>**

**Two stat  
for TENSION  
headache**

**SANDOZ<sup>®</sup>**  
▲▲▲

Complete headache therapy

Sandoz Canada Inc., Dorval, Quebec H9B 4P5

Fiorinal contains: ASA/caffeine/butalbital  
Full prescribing information available on  
request

TM  
PAAB  
CCPP  
PMAAC  
ACIM